| 2025-04-24 | -0.22 % |
|
| 2025-04-23 | +0.82 % |
|
| 2025-04-21 | -0.2 % |
|
| 2025-04-17 | -0.32 % |
|
| 2025-04-16 | -0.76 % |
|
| 2025-04-11 | +2.2 % |
|
| 2025-04-09 | +2 % |
- Gilead Sciences (GILD) stock rose by 2.0% due to strong fourth-quarter earnings growth and positive news regarding its HIV prevention drug Lenacapavir, which is under review for U.S. approval, along with favorable reception of its cirrhosis treatment, Livdelzi.
- Gilead Sciences (GILD) stock rose by 2.0% last night, potentially due to strong interest and confidence in its strategic collaborations, such as with Tango Therapeutics, which enhance its drug development pipeline in oncology.
- Gilead Sciences (GILD) stock was up 2.0% recently, likely due to positive market sentiment surrounding its strategic collaborations and ongoing developments in its therapeutic areas, which may signal potential growth and solid returns for investors.
- Gilead Sciences (GILD) stock rose 2.0% due to positive market sentiment and potential investment interest, particularly involving new stakes purchased by hedge funds in Arcus Biosciences, which may enhance collaborative opportunities and strategic positioning in the biopharmaceutical sector.
|
| 2025-04-08 | -2.21 % |
|
| 2025-04-03 | +0.45 % |
|
| 2025-04-02 | +0.55 % |
|
| 2025-04-01 | -0.69 % |
|
| 2025-03-27 | +1.73 % |
|
| 2025-03-25 | +1.08 % |
|
| 2025-03-21 | +1.14 % |
|
| 2025-03-20 | -1.53 % |
|
| 2025-03-19 | -2.47 % |
|
| 2025-03-18 | -1.81 % |
|
| 2025-03-14 | -1.69 % |
|
| 2025-03-13 | -0.56 % |
|
| 2025-03-11 | -2.37 % |
|
| 2025-03-10 | -0.17 % |
|
| 2025-03-07 | +1.18 % |
|
| 2025-03-06 | +0.52 % |
|
| 2025-03-05 | +0.61 % |
|
| 2025-03-04 | -1.08 % |
|
| 2025-02-27 | +1.39 % |
|
| 2025-02-18 | +1.12 % |
|
| 2025-02-14 | -1.77 % |
|
| 2025-02-10 | -0.58 % |
|
| 2025-02-07 | -2.04 % |
|
| 2025-02-06 | -1.62 % |
|
| 2025-02-05 | +1.69 % |
|
| 2025-02-04 | -0.4 % |
|
| 2025-01-24 | +0.16 % |
|
| 2025-01-22 | +0.09 % |
|
| 2025-01-21 | +1.22 % |
|
| 2025-01-17 | +0.21 % |
|
| 2025-01-16 | -0.79 % |
|
| 2025-01-13 | +0.07 % |
|
| 2025-01-08 | -1.64 % |
|
| 2025-01-07 | -0.66 % |
|
| 2025-01-06 | -0.2 % |
|
| 2025-01-03 | -0.51 % |
|
| 2025-01-02 | -0.53 % |
|
| 2024-12-31 | +0.39 % |
- Gilead Sciences (GILD) stock rose by 0.39% due to a combination of positive market sentiment and potential increased demand for its pharmaceutical products, although specific reasons for this rise were not detailed in the provided article.
- The article discusses Representative Marjorie Taylor Greene's recent stock purchases, including Gilead Sciences, which rose by 0.39% last night, although it does not provide specific reasons for this increase. The rise in Gilead Sciences (GILD) stock may be attributed to overall market conditions, investor sentiment, or specific developments in the company that were not detailed in the article.
- Gilead Sciences (GILD) stock rose 0.39% likely due to positive market sentiment following recent trading activity and analysis trends, though the article primarily discusses Representative Marjorie Taylor Greene's purchase of Adobe shares rather than specific factors affecting Gilead's stock.
- The article discusses a recent increase of 0.39% in Gilead Sciences (GILD) stock, which may be influenced by various factors, including overall market trends, investor sentiment, or specific actions taken by notable investors like Representative Marjorie Taylor Greene purchasing shares, although these details about Gilead are not explicitly mentioned in the provided text.
- The article discusses the recent stock activity of Norfolk Southern Co. and mentions that Gilead Sciences (GILD) stock increased by 0.39%. Gilead Sciences stock's increase could be attributed to overall positive market sentiment, potential favorable developments in their drug portfolio, or investor activity, but specific reasons related to GILD were not detailed in the article provided.
- Gilead Sciences (GILD) stock rose by 0.39% likely due to positive investor sentiment following recent disclosures of stock purchases by Representative Marjorie Taylor Greene and a strong quarterly earnings report that exceeded analysts' expectations.
|
| 2024-12-19 | +0.44 % |
|
| 2024-12-18 | -2.27 % |
|
| 2024-12-17 | +0.81 % |
|
| 2024-12-16 | +0.21 % |
|
| 2024-12-12 | |
|
| 2024-12-02 | +1.56 % |
|
| 2024-11-26 | +0.95 % |
|
| 2024-11-25 | +0.33 % |
|
| 2024-11-21 | +1.27 % |
|
| 2024-11-20 | +1 % |
|
| 2024-11-07 | +6.77 % |
|
| 2024-11-06 | +1.63 % |
|
| 2024-11-05 | +0.42 % |
|
| 2024-11-04 | +0.37 % |
|
| 2024-11-01 | +0.78 % |
|
| 2024-10-31 | +0.6 % |
|
| 2024-10-30 | +0.24 % |
|
| 2024-10-28 | -0.27 % |
|
| 2024-10-25 | +0.25 % |
|
